June 13, 2018
InSysBio LLC (www.insysbio.com), a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a collaboration with GSK, one of the world’s leading research-based pharmaceutical and healthcare companies, for development of QSP platform of Chronic Obstructive Pulmonary Disease (COPD).
The aim of collaboration is to develop a comprehensive QSP platform of COPD and its treatment including detailed description of immune cell dynamics, effect of cigarette smoke, extracellular matrix remodeling and other aspects of disease progression.
About InSysBio
InSysBio (formerly Institute for System Biology Moscow) was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of quantitative systems pharmacology (QSP) modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published a lot of scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | February 2021 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
|
15
1.
15 Feb 2021 15:19
InSysBio to be interviewed in frames of INNOVATORS VS COVID-19 series
[Moscow – 15.02.2021] Oleg Demin Jr, Head of Oncology and Immuno-Oncology at InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, has talked to startup.info, a global innovation ecosystem magazine. The interview in frames of the series "INNOVATORS VS COVID-19" covers the application of system-pharmacology modeling to different stages of drug research and development and InSysBio's current development in the context of the pandemic.
|
16
|
17
|
18
|
19
|
20
|
21
|
|
22
|
23
|
24
|
25
|
26
|
27
|
28
|
Thank you for your message! We will get back to you shortly.
